April 8, 2026 • Vol. 1, Issue 4
We welcome inquiries, tips, letters to the editor, and article ideas from the MBS community. Reach us at [email protected] — your submissions help shape what we cover.
Invited surgeon commentaries are forthcoming. If you are interested in contributing a perspective or editorial on a topic relevant to metabolic and bariatric surgery, please contact us at [email protected].
Cannabis Use Rises 52% After Bariatric Surgery — Alcohol Use a Key Driver
A survey-based study from a single Michigan health system examined legal cannabis use patterns among 612 patients who underwent MBS between 2018 and 2021, documenting a 52.4% relative increase in cannabis use prevalence from pre- to post-MBS. Among the 16% of participants who reported postoperative cannabis use, nearly half (45.9%) were new initiates with no preoperative cannabis history. Past-year hazardous alcohol use was independently associated with nearly three times the odds of persisting in cannabis use post-MBS (adjusted OR 3.0; 95% CI 1.6–5.8) and 2.8 times the odds of newly initiating use after surgery (95% CI 1.4–5.4). The findings raise concern about a shared post-MBS behavioral risk pathway for substance substitution and suggest that patients with hazardous alcohol use warrant closer monitoring for cannabis use during postoperative follow-up.
Surg Obes Relat Dis — doi:10.1016/j.soard.2025.11.027Patients screening positive for hazardous alcohol use had nearly 3× the odds of initiating or persisting in cannabis use post-MBS — reinforcing the need for integrated substance use screening in bariatric follow-up protocols.
MASLD Identified as Independent Risk Factor for Porto-Mesenteric Venous Thrombosis After Sleeve Gastrectomy
A retrospective matched case-control study from the Hamad Medical Corporation (Qatar) analyzed 38 confirmed porto-mesenteric venous thrombosis (PMVT) cases against 152 matched controls following laparoscopic sleeve gastrectomy. Metabolic dysfunction-associated steatotic liver disease (MASLD) emerged as the single independent predictor of PMVT, carrying an adjusted OR of 2.95 (95% CI 1.028–8.467; p=0.044). The vast majority of events — 92.1% — occurred within 30 days of surgery, with abdominal pain as the most common presenting symptom. Combined portal and superior mesenteric vein thrombosis was the predominant radiological pattern (63.2%). Anticoagulation was required for at least six months in most patients; complete recanalization was achieved in only 9.4% at follow-up. Two patients (5.3%) died within 90 days. The authors suggest hepatic metabolic dysfunction may represent an underrecognized driver of post-LSG thrombotic vulnerability.
Obes Surg — doi:10.1007/s11695-026-08637-x92.1% of PMVT cases occurred within 30 days of LSG. MASLD — identifiable preoperatively by hepatic steatosis on imaging — was the only independently significant risk factor, nearly tripling the odds.
Bariatric Surgery Associated with 79% Reduction in Osteoarthritis Odds: Systematic Review and Meta-Analysis
This open-access systematic review and meta-analysis pooled evidence from 12 cohort studies encompassing over 12,000 patients to evaluate the effect of metabolic bariatric surgery on osteoarthritis-related outcomes. Pooled analysis using a random-effects model demonstrated a 79% reduction in the odds of osteoarthritis diagnosis following surgery compared to preoperative status (OR 0.21; 95% CI 0.11–0.41). Clinically meaningful improvements were observed across all three WOMAC subscales — pain, stiffness, and physical function — at both 6 and 12 months postoperatively. Pooled WOMAC improvement at 12 months was −17.12 points (95% CI −25.28 to −8.96). Heterogeneity was substantial across studies (I² >75%), reflecting variability in procedures, populations, and follow-up duration. The authors conclude that surgical weight loss confers meaningful musculoskeletal benefits extending well beyond metabolic and cardiovascular endpoints.
World J Surg — doi:10.1002/wjs.7023679% reduction in odds of OA diagnosis after bariatric surgery across 12 studies and 12,000+ participants. WOMAC scores improved significantly across all three domains at 6 and 12 months.
Small-Bites Fascial Closure Reduces Incisional Hernia by 31% at 13 Years: Long-Term STITCH Trial Data
Long-term follow-up from the multicenter double-blind STITCH randomized clinical trial — which enrolled 559 patients undergoing elective midline laparotomy across 10 centers in the Netherlands — reports outcomes at 13 years. Cumulative incisional hernia incidence was 34% in the small-bites group versus 49% in the large-bites group (hazard ratio 0.61; 95% CI 0.43–0.86). For clinically significant hernias wider than 20 mm, the advantage was more pronounced: 17% versus 34% (HR 0.36; 95% CI 0.21–0.60). Hernias were significantly smaller at final follow-up in the small-bites group (mean 25 mm vs. 43 mm; P=.02). Hernia repair rates were similar between groups. The authors argue these durable findings confirm small-bites closure (5 mm × 5 mm) as the standard of care for midline laparotomy — with direct relevance for bariatric surgeons performing open or converted cases.
JAMA Surg — doi:10.1001/jamasurg.2026.061813-year data confirm small-bites fascial closure reduces incisional hernia incidence by 31% and produces significantly smaller hernias compared to large-bites technique. Authors recommend universal adoption as standard practice.
Perioperative Management of GLP-1s and Cardiovascular Medications: 2024 AHA/ACC Guidelines Summarized
This JAMA Clinical Guidelines Synopsis distills the 2024 American Heart Association/American College of Cardiology recommendations on perioperative cardiovascular medication management for noncardiac surgery — with direct implications for bariatric and metabolic surgery programs. An estimated 14 million inpatient and 19 million ambulatory operations are performed annually in the United States, a growing proportion of which involve patients on complex cardiovascular and metabolic medication regimens. The synopsis addresses five drug classes with particular clinical urgency: GLP-1 receptor agonists, SGLT-2 inhibitors, statins, beta-blockers, and antiplatelet agents. GLP-1 agonist guidance is especially pertinent for bariatric programs, as patients who have been using these agents preoperatively — or who may restart them for weight regain post-surgery — require coordinated perioperative planning to manage delayed gastric emptying and aspiration risk. The SGLT-2 inhibitor recommendations carry equal relevance given the high prevalence of type 2 diabetes and cardiovascular comorbidities across the MBS patient population.
JAMA — doi:10.1001/jama.2026.0067As GLP-1 and SGLT-2 agents become increasingly prevalent in the bariatric patient population, 2024 AHA/ACC perioperative guidance on their management — including hold periods and restart protocols — is now essential working knowledge for MBS programs and anesthesia partners.
Expanded Medicare GLP-1 Coverage Would Add $47.7 Billion in Net Spending Over 10 Years
A 10-year fiscal impact analysis using the validated Diabetes, Obesity, Cardiovascular Disease Microsimulation model estimated the net federal cost of expanding Medicare Part D coverage to GLP-1 receptor agonists for obesity treatment across 30 million eligible beneficiaries. In the base-case scenario — 10% uptake, 40% adherence — Medicare drug spending was projected at $65.9 billion over 10 years. Long-term health care savings from reduced obesity-related comorbidities were estimated at $18.2 billion, yielding a net spending increase of $47.7 billion. Even conservative scenarios combining lower uptake (5%), higher price discounts (30%), and reduced adherence (20%) still produced net spending increases of $8 billion or more over the decade. The authors conclude that expanded GLP-1 coverage is clinically beneficial but fiscally significant, and that meaningful cost reduction would require further Inflation Reduction Act price negotiations, lower-cost weight regain prevention strategies, and reductions in low-value care utilization.
JAMA Health Forum — doi:10.1001/jamahealthforum.2025.0905Base-case 10-year projection: $65.9B drug cost, offset by $18.2B health savings = net $47.7B increase in Medicare spending. Even low-uptake, high-discount scenarios add $8B+.
CMS BALANCE Model: What Clinicians and Patients Need to Know
The CMS BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive Health) model, announced December 23, 2025, establishes a voluntary framework under which CMS negotiates standardized pricing and coverage terms for FDA-approved obesity medications — including GLP-1 and GIP/GLP-1 dual agonist drugs — for Medicare and Medicaid beneficiaries. Eligible medications must demonstrate at least 10% mean body weight reduction in randomized controlled trials. Medicaid programs may join in May 2026, Part D plans in January 2027; a Part D bridge program offering patient access at a $50 monthly co-pay launches in July 2026. The authors note that program success hinges on voluntary participation from both state Medicaid agencies — 16 of which have recently reversed GLP-1 coverage commitments due to budget constraints — and private Part D plans weighing the financial tradeoffs. They support BALANCE as a meaningful policy signal that obesity is a disease requiring medical management, but call for robust financial incentives to secure plan and state participation at scale.
JAMA — doi:10.1001/jama.2026.2894CMS BALANCE model opens Part D bridge access July 2026 at $50/month co-pay. Coverage is voluntary — success depends on drug manufacturers, insurers, and state Medicaid programs opting in by respective deadlines.
Trump’s Medicare GLP-1 Expansion Faces Insurer Cost Hurdle — Opt-In Deadline April 20
The Trump administration’s CMS-backed BALANCE program faces a critical participation threshold: private insurers covering at least 80% of Medicare enrollees must elect to participate by April 20, 2026 for the program to proceed. A Vanderbilt University analysis published in JAMA found that first-year GLP-1 drug pricing savings of $900 million would cover expanded coverage costs for approximately 4.4% of newly eligible patients — well short of anticipated demand. CMS Director Mehmet Oz has argued that negotiated pricing with Eli Lilly and Novo Nordisk will expand access without burdening taxpayers, while independent researchers caution that insurer participation at scale would require premium increases to remain solvent. The administration secured manufacturer cooperation in part by offering a Medicare coverage pathway for GLP-1 obesity medications in exchange for “most favored nation” pricing agreements — a tradeoff that now hinges on insurers accepting the terms.
Bloomberg via Yahoo Finance — April 2, 2026Insurer opt-in deadline: April 20, 2026. Program requires plans covering 80% of Medicare enrollment to participate. Vanderbilt analysis: first-year savings cover only ~4.4% of newly eligible patients.
FDA Approves Foundayo™ (Orforglipron) — First Oral GLP-1 Pill Without Food or Water Restrictions
The FDA approved Foundayo™ (orforglipron) on April 1, 2026 — the first small-molecule GLP-1 receptor agonist pill approved for the treatment of obesity and overweight with weight-related comorbidities in adults. Unlike existing oral semaglutide formulations, Foundayo can be taken at any time of day without food or water restrictions, removing a significant barrier to adherence. The approval was issued 50 days after filing and 294 days ahead of the scheduled PDUFA date, representing the fastest new molecular entity approval since 2002. In the pivotal Attain-1 trial, participants on the highest dose (5.5 mg once daily) achieved a mean body weight reduction of 12.4% (27.3 lbs) at 72 weeks, versus 0.9% with placebo. Dosing begins at 0.8 mg daily, titrating to 2.5 mg after 30 days, then to 5.5 mg after an additional 30 days. Patients with commercial insurance may access Foundayo for as little as $25 per month with a savings card; self-pay pricing starts at $149 per month. Medicare Part D enrollees will have access at $50 per month beginning July 1, 2026, aligning with the CMS BALANCE bridge program timeline.
Eli Lilly Investor Relations — April 1, 2026The first oral GLP-1 approved without dosing restrictions removes a key adherence barrier. MBS programs should anticipate greater patient interest in pharmacotherapy upstream of surgical referral — and will need perioperative protocols specifically addressing orforglipron hold and restart timing.
Obesity Medicine Association Launches OMAr — AI-Powered Patient Simulation Tool for Clinician Training
The Obesity Medicine Association (OMA) launched OMAr, an AI-powered interactive patient simulator designed to help clinicians practice obesity treatment conversations in a risk-free environment before engaging real patients. Available at TreatingObesityFirst.org and released April 3, 2026, the tool guides users through the evidence-based “5As” framework — Ask, Assess, Advise, Agree, Assist — with realistic simulated patient scenarios, a structured discussion guide, and free continuing medical education (CME) credit. The platform is intended for physicians, nurse practitioners, physician assistants, and other providers who work with patients with obesity. OMAr addresses a recognized gap in clinician confidence around initiating these discussions, where stigma, misinformation, and uncertainty about pharmacotherapy options remain persistent barriers. “The hardest part of a conversation about obesity is simply starting it,” noted OMA Board member Dr. Courtney Younglove.
Obesity Medicine Association — April 3, 2026OMAr is free, CME-eligible, and available now at TreatingObesityFirst.org. Uses the 5As framework to build clinician confidence in obesity care conversations — relevant for primary care partners and MBS program patient educators.
Foundayo Launch Ignites GLP-1 Pricing Battle — Efficacy Gap Remains Lilly’s Headwind
Despite the historic significance of Foundayo’s FDA approval, competitive pricing dynamics have tempered Eli Lilly’s post-approval stock performance. Analyst projections for 2026 Foundayo revenue range from $1.5 billion to $2.8 billion, with Citi at the bullish end; the combined oral GLP-1 weight-loss market is anticipated to approach $5 billion this year. Foundayo launched via LillyDirect at $149 per month — identical to Wegovy’s cash price — with a three-month head start before Wegovy’s full retail rollout. However, a meaningful clinical gap persists: Foundayo’s 12.4% mean weight loss at 72 weeks compares unfavorably to Wegovy oral’s 16.6%, a 4.2-percentage-point difference that Leerink analysts and others view as a durable commercial headwind. Foundayo’s primary advantages are convenience and access — no food or water restrictions, any-time dosing — which may prove decisive among patients and prescribers prioritizing simplicity and adherence over maximum weight reduction.
GEN — April 6, 2026Combined oral GLP-1 market projected at ~$5B in 2026. Foundayo revenue estimate: $1.5–2.8B. Key headwind: 4.2% efficacy gap vs. Wegovy. Key advantage: pricing parity, no dosing restrictions, 3-month retail head start.
Novo Nordisk Initiates Phase 1 for LX9851 — Novel Oral ACSL5 Inhibitor for Obesity
Novo Nordisk and Lexicon Pharmaceuticals announced initiation of a Phase 1 study for LX9851, an oral small-molecule inhibitor of acyl-CoA synthetase 5 (ACSL5) — a novel obesity target distinct from the GLP-1 pathway. Novo Nordisk holds exclusive worldwide rights to develop, manufacture, and commercialize LX9851 across all obesity-related indications under a license executed in March 2025. The Phase 1 trial enrolls 96 adults with overweight or obesity in a single and multiple ascending dose design evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics, with results expected by Q1 2027. Lexicon earned a $10 million milestone upon initiation of dosing, with a second $10 million milestone potentially achievable later in 2026. Total potential milestone payments reach up to $1 billion, plus tiered royalties. The program represents Novo Nordisk’s effort to build a mechanistically differentiated pipeline as GLP-1 pricing compresses under competitive and regulatory pressure.
StockTitan / Lexicon Pharmaceuticals — March 23, 2026LX9851 is a non-GLP-1 oral obesity mechanism (ACSL5 inhibition) — Novo Nordisk’s hedge against GLP-1 commoditization. Up to $1B in Lexicon milestones; Phase 1 results expected Q1 2027.
Neurocrine Biosciences Acquires Soleno for $2.9B — Secures Vykat XR for Prader-Willi Syndrome
Neurocrine Biosciences announced a $2.9 billion acquisition of Soleno Therapeutics on April 6, 2026, adding Vykat XR — an approved treatment for extreme hunger (hyperphagia) in Prader-Willi syndrome (PWS) — to its commercial portfolio. The $53-per-share offer represents a 51% premium over Soleno’s 30-day volume-weighted average. Vykat XR generated $190.4 million in first-year sales with approximately 1,250 patients on therapy; BMO Capital Markets projects 2026 sales of $450 million, with worldwide sales potentially exceeding $2 billion by the mid-2030s. RBC Capital Markets described the deal as strategically sound given Neurocrine’s existing pediatric endocrinology presence and salesforce synergies. The acquisition signals that genetically driven, syndromic obesity disorders — where hyperphagia is neurobiological rather than behavioral — are emerging as commercially viable rare-disease targets, distinct from and complementary to the broader GLP-1 market.
BioSpace — April 6, 2026Prader-Willi hyperphagia is neurobiologically driven, not lifestyle-related — reflecting industry recognition that severe genetic obesity disorders require dedicated pharmacotherapy beyond the GLP-1 pathway.
Ohio’s First Magnetic Compression Bariatric Procedure Performed at Summa Health — MAGDI System
Summa Health in Akron, Ohio became the first facility in the state to offer the MAGDI system, a minimally invasive bariatric technology that creates connections between digestive tract segments using magnetic compression rather than surgical incisions. The device deploys magnets to progressively compress and fuse targeted sections of the gastrointestinal tract, reducing procedural trauma and potentially improving safety and recovery compared to conventional bariatric operations. The article featured a patient case report (Trevor Paisley) but comprehensive clinical trial data and comparative effectiveness statistics were not yet available in initial reporting. MAGDI represents an emerging class of endoluminal magnetic-assisted bariatric technologies with potential implications for patient selection in cases where traditional surgical access is limited, patient risk profile is elevated, or minimally invasive revision is required.
Signal Akron — April 4, 2026MAGDI is the first magnetic compression bariatric system deployed in Ohio. No comparative effectiveness data yet published. An emerging option worth tracking for high-risk or access-limited bariatric candidates.
| Sector | Ticker | Company | Feb 9 Open | Apr 6 Close | 2-Mo Chg |
|---|---|---|---|---|---|
| Robotics/MIS | ISRG | Intuitive Surgical | $492.84 | $452.58 | -8.2% |
| MedTech | MDT | Medtronic | $100.83 | $86.28 | -14.4% |
| MedTech | BSX | Boston Scientific | $74.12 | $62.59 | -15.6% |
| MedTech | TFX | Teleflex | $105.90 | $115.04 | +8.6% |
| Pharma/GLP-1 | LLY | Eli Lilly | $1,042.93 | $927.06 | -11.1% |
| Pharma/GLP-1 | NVO | Novo Nordisk | $47.62 | $36.67 | -23.0% |
| Pharma | AMLX | Amylyx Pharma | $14.22 | $15.82 | +11.3% |
| Pharma | PFE | Pfizer | $27.05 | $27.83 | +2.9% |
| MedTech | ABT | Abbott Labs | $111.07 | $102.30 | -7.9% |
| Pharma | AMGN | Amgen | $373.23 | $342.57 | -8.2% |
| Pharma | VTRS | Viatris | $15.43 | $13.41 | -13.1% |
| Pharma | JNJ | Johnson & Johnson | $237.38 | $240.97 | +1.5% |
Zacks downgraded ISRG to Hold in April 2026, citing rising competition from rival robotic surgery platforms, regulatory uncertainty, and shifting hospital capital spending patterns. Shares fell 17.6% in the first 21 trading days of the period following a cautious Q4 2025 read-through; year-to-date losses reached 19.4% by end of March. Institutional accumulation continued, with Nisa Investment Advisors increasing its stake 3.2% in Q4. ISRG also announced AI-enhanced surgical precision features for the da Vinci platform, reinforcing its longer-term competitive moat despite near-term multiple compression.
Medtronic collected three regulatory wins during the period: FDA clearance for the Stealth AXiS™ surgical navigation system, FDA approval for the OmniaSecure™ defibrillation lead, and a new partnership with Merit Medical for the ViaVerte™ vertebrogenic back pain system. Despite those milestones, MDT faces a structural competitive squeeze: Boston Scientific’s $14.5B Penumbra acquisition directly targets MDT’s neurovascular franchise, while Stryker continues to press aggressively in spine and orthopedics. Analysts view the stock as undervalued at current levels, with consensus price targets implying meaningful upside.
Boston Scientific’s $14.5 billion acquisition of Penumbra — announced January 15, 2026 and the largest deal in BSX history — firmly repositions the company in neurovascular devices. The near-term share price decline reflects dilution concerns, integration execution risk, and a securities class-action lawsuit alleging insufficient disclosure of an electrophysiology sales slowdown. Stifel maintained a Buy rating with a $90 target ahead of the CHAMPION-AF data presentation on March 28; the stock, trading around $63, implies approximately